Understanding how gene therapy affects blood cancer treatment
Comprehensive Characterization of LVV Integration and Impact on Host Cell Biology using Novel Genomic Technologies
This study is looking at how a special type of gene therapy, used to treat blood cancers like acute lymphoblastic leukemia, affects the way our cells work and how they might cause side effects, with the hope of making these treatments safer and more effective for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10998612 on NIH RePORTER |
What this research studies
This research investigates the integration of lentiviral vectors (LVVs) into host DNA and their impact on cellular biology, particularly in the context of treating blood cancers like acute lymphoblastic leukemia. By utilizing novel genomic technologies, the study aims to characterize how these vectors influence gene expression and alternative splicing patterns in patients receiving CAR T-cell therapies. The goal is to better understand the mechanisms behind potential adverse effects, such as cellular transformation, which have been linked to these therapies. This research could provide insights that improve the safety and efficacy of gene therapies for blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute lymphoblastic leukemia or other B cell malignancies who are considering or have undergone CAR T-cell therapy.
Not a fit: Patients with solid tumors or those not receiving CAR T-cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for patients with blood cancers.
How similar studies have performed: Previous research has shown promise in understanding LVV integration and its effects, but this specific approach is novel and aims to address recent safety concerns.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Kaiser, Catherine — University of Louisville
- Study coordinator: Kaiser, Catherine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.